Last reviewed · How we verify
Antihyperglycemic Drug
Antihyperglycemic drugs lower blood glucose levels through various mechanisms such as enhancing insulin secretion, improving insulin sensitivity, or reducing hepatic glucose production.
Antihyperglycemic drugs lower blood glucose levels through various mechanisms such as enhancing insulin secretion, improving insulin sensitivity, or reducing hepatic glucose production. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Antihyperglycemic Drug |
|---|---|
| Sponsor | Sanofi |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
This is a broad drug class rather than a single entity. Sanofi manufactures multiple antihyperglycemic agents including sulfonylureas, meglitinides, biguanides, thiazolidinediones, DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT2 inhibitors. Each class works through distinct mechanisms to reduce hyperglycemia in diabetes management.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Gastrointestinal disturbances
- Weight changes
Key clinical trials
- Vascular Complications in Patients Undergoing Peripheral Revascularization and Taking SGLT-2 Inhibitors
- SGLT2i Improve Left Atrial Function in Patients With Paroxysmal Atrial Fibrillation, Hypertension and Abnormal Glucose Metabolism (PHASE2)
- Ameliorating Metabolic Profiling After Kidney Transplantation (AMPKT) (NA)
- The Use of Advanced Imaging in HFpEF
- Safety and Effectiveness of Overripe Banana Powder Added to Diabetic Formulas in Type 2 Diabetes (NA)
- Early Add-On Combination of GLP-1 Receptor Agonist and SGLT2 Inhibitor in People With Cardiovascular-Kidney-Metabolic Stage 2-3
- A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes (PHASE3)
- Effect of Liraglutide in Obese Women With Polycystic Ovary Syndrome (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Antihyperglycemic Drug CI brief — competitive landscape report
- Antihyperglycemic Drug updates RSS · CI watch RSS
- Sanofi portfolio CI